CCL2 and plasma cell myeloma: Myeloma: PEDF decreases vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), intercellular cell adhesion molecule-1 (ICAM-1) and plasminogen activator inhibitor-1 (PAI-1) mRNA levels in myeloma cells, through its signalling via the laminin receptor (LR) [39].